Evgen

Evgen is a biotechnology company focused on developing therapeutics for behavioral brain disorders, including anxiety and substance use disorders, with innovative drug candidates aimed at improving patient outcomes. Evgen specializes in therapeutics for behavioral brain disorders, with a presence in Liverpool, UK. Founded by individuals with prior experience in the field, the company completed an IPO in October 2015. It has raised a total of GBP 0.

460 mn with the latest funding round attracting investments from Mercia Asset Management and North West Business Finance. The current valuation of Evgen stands at GBP 3. 643 mn, with Huw Jones serving as CEO. Evgen develops innovative therapeutics targeting behavioral brain disorders, focusing on three primary drug candidates: Ox-1, which addresses addictive behaviors and anxiety; DAT, aimed at alleviating central fatigue; and SFX-01, which targets glioblastoma tumors.

These products are in various stages of preclinical development, with Ox-1 approaching Phase 1 human trials, and the company is seeking partnerships for broader market access in North America and Europe. In the most recent fiscal year of 2022, Evgen reported a revenue of GBP 0 and an EBITDA of GBP -258,956. 60. The company's revenue model centers on partnerships with larger pharmaceutical firms for the clinical development and commercialization of its drug candidates, anticipating milestone payments and royalties upon product launch.

Evgen is focused on advancing its drug candidates Ox-1, DAT, and SFX-01 through clinical trials, with a strategic emphasis on launching these products in North America and Europe by specific dates yet to be disclosed. The funding raised in October 2015 will support ongoing development and regulatory processes, helping to facilitate the company's entry into these markets.